Pfizer announced that the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee, VRBPAC, voted that available data is adequate to support the safety and effectiveness of its respiratory syncytial virus bivalent vaccine candidate PF-06928316 or RSVpreF. The Committee voted 7 to 4 on safety and 7 to 4 on effectiveness. The vaccine candidate is currently under FDA review for the prevention of acute respiratory disease and lower respiratory tract disease caused by RSV in adults 60 years of age and older.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PFE:
- Moderna, Pfizer: Top mRNA Innovator Stocks are Oversold
- FDA advisors back safety of Pfizer RSV vaccine
- FDA Virtual Vaccines & Related Biological Products Advisory Committee Meeting
- Seagen price target raised to $210 from $180 at Oppenheimer
- Pfizer acquisition of Seagen could add $7B in sales, says JPMorgan